Abstract
The identification of multiple molecular drivers of lung cancer and development of targeted therapies has led to changes in biomarker testing for metastatic non-small cell lung cancer (mNSCLC). The MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) consortium pragmatic study evaluated real-world trends in molecular testing rates and assays used in patients with mNSCLC receiving care in US Oncology Network practices across the United States.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
